Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population by FengHe Cui et al.
Cui et al. Lipids in Health and Disease 2014, 13:170
http://www.lipidworld.com/content/13/1/170RESEARCH Open AccessApolipoprotein C3 genetic polymorphisms are
associated with lipids and coronary artery disease
in a Chinese population
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Background: The disorder of triglyceride (TG) metabolism leading to hypertriglyceridemia is an independent risk
factor for coronary artery disease (CAD). Variants in the apolipoprotein C3 (APOC3) gene were found to be
associated with elevated TG levels. The purpose of this study was to investigate the effect of two polymorphisms
(1100 C/T and 3238 C/G) of APOC3 on plasma lipid and risk of CAD in a Chinese population.
Methods: The study population consisted of 600 patients with CAD and 600 age- and gender-matched controls.
The APOC3 gene polymorphism was analyzed using polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP).
Results: Patients with CAD had a significantly higher frequency of APOC3 3238 GG genotype [odds ratio
(OR) =1.64, 95% confidence interval (CI) =1.10, 2.43; P = 0.01] and APOC3 3238 G allele (OR =1.27, 95% CI =1.04,
1.55; P = 0.02) than controls. The findings are still emphatic by the Bonferroni correction. When stratifying by
hyperlipidemia, CAD patients with hyperlipidemia had a significantly higher frequency of APOC3 3238 GG genotype
(OR =1.73, 95% CI =1.13, 2.64; P = 0.01) than without hyperlipidemia. The APOC3 3238 G allele was significantly
associated with increasing plasma TG levels and very-low-density lipoprotein cholesterol (VLDL-C) levels both in
cases and controls (P < 0.001).
Conclusions: The APOC3 3238 G allele might contribute to an increased risk of CAD as a result of its effect on TG
and VLDL-C metabolism.
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Coronary artery disease (CAD), one of the most common
cardiovascular diseases, is the leading cause of morbidity
and mortality worldwide [1]. It is caused by multiple inter-
acting endogenous and exogenous factors [2]. There
are several emerging risk factors for CAD including
smoking, obesity, stress, diabetes, lack of exercise, high
alcohol consumption, and hyperlipidemia [3]. Genetic
risk, estimated to account for 40-60% of susceptibility
to CAD, has until recently been unknown [4-7]. Recently,* Correspondence: csan2003@outlook.com
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unless otherwise stated.genome-wide association studies (GWAS) identified a
series of single-nucleotide polymorphisms (SNPs) associ-
ated with CAD [8-10].
Apolipoprotein C3 (APOC3), a component of trigly-
ceride (TG)-rich lipoproteins and high-density lipo-
protein (HDL), was mainly synthesized in the liver and to
some extent in the intestine [11]. APOC3 gene, mapped to
chromosome 11q23, was involved in transport and clear-
ance of chylomicron remnants, and very-low-density lipo-
protein (VLDL) and HDL from the bloodstream [12,13].
Two common SNPs have been identified in the APOC3
gene: 1100 C/T and 3238 C/G [14,15]. The APOC3 3238
C/G polymorphisms have been found to be associated
with altered plasma TG concentrations [16].
Recently, case–control study has suggested that the
APOC3 3238G allele was a risk factor for CAD in Indians. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 General characteristics of cases and controls
CAD Controls P
Number of subjects 600 600
Age (years), mean(SD) 57.3 ± 10.8 56.9 ± 10.1 0.51
Gender (Male/Female) 486/114 462/138 0.09
Smoking status (Ever/Never) 192/408 98/502 <0.001
Family history (Positive/Negative) 98/502 77/523 0.09
Hypertension (Positive/Negative) 305/295 280/320 0.15
Diabetes (Positive/Negative) 156/444 78/522 <0.001
Obesity (Positive/Negative) 176/424 85/515 <0.001
Hyperlipidemia (Positive/Negative) 188/412 92/508 <0.001
TG (mg/dL) 180.5 ± 92.3 151.7 ± 79.4 <0.001
TC (mg/dL) 202.1 ± 60.2 189.6 ± 47.9 <0.001
HDL-C (mg/dL) 37.4 ± 11.3 39.5 ± 12.4 0.002
LDL-C (mg/dL) 124.8 ± 49.8 116.7 ± 35.4 0.001
VLDL-C (mg/dL) 39.8 ± 23.7 32.7 ± 19.5 <0.001
ApoA1 (mg/dL) 127.3 ± 23.7 126.8 ± 22.9 0.71
ApoB (mg/dL) 90.6 ± 28.7 89.7 ± 24.5 0.56
Abbreviations: CAD coronary artery disease, TG triglyceride, TC total cholesterol,
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
VLDL-C very-low-density lipoprotein cholesterol, Apo apolipoprotein.
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finding, and no similar studies were represented in
Chinese. The purpose of this study was to investigate
the effect of two polymorphisms (1100 C/T and 3238 C/G)




A hospital-based case–control study was carried out
in 600 patients with CAD and 600 age- and gender-
matched controls from January 2012 to January 2014 in
the Yantai Yuhuangding Hospital and Clinical College
of Yanbian University, China. Based on WHO criteria,
CAD cases were defined as those having severe angios-
tenosis (>50%) in at least one major coronary artery
determined by angiography. The control group was
composed of age- and gender-matched subjects who
had undergone a coronary angiography in the same
recruitment period as the CAD patients, without angio-
graphic evidence of CAD. Controls selected also had at
least one conventional predisposing factor of CAD.
The controls were required to have no history or ECG
signs of angina pectoris, myocardial infarction, or other
cardiovascular diseases. In addition, similar to the cases
the controls were all required to be born in China to
native Chinese Han parents. To confirm the diagnosis,
two physicians reviewed the hospital records and validated
each case. The Institutional Ethical Committee approved
this study, and all participants gave written informed
consent according to the Declaration of Helsinki.
DNA extraction and genotyping
The commercially available Qiagen kit (QIAGEN Inc.,
Valencia, CA, USA) was used to extract DNA from per-
ipheral blood leukocytes. Genomic DNA was isolated
from 20 g/L ethylenediaminetetraacetic acid (EDTA) or
sodium citrate anticoagulated 3–5 ml venous blood and
stored at 4°C. Polymerase chain reaction restriction
fragment length polymorphism (PCR-RFLP) assay was
applied to assess the APOC3 gene polymorphisms.
Based on the GenBank reference sequence, the PCR
primers designed for APOC3 1100 C/T and 3238 C/G
were 5′-AGA GGC CGA TCC ACC CCA CTC AGC C-
3′ (forward) and 5′-GGC GGT CTT GGT GGC GTG
CTT CAG G-3′ (reverse); 5′-CAT GGT TGC CTA
CAG AGG AGT-3′ (forward) and 5′-TGA CCT TCC
GCA CAA AGC TGT-3′ (reverse), respectively. The
amplified PCR products were digested with SstI (3238
C/G) and SacI (1100 C/T) (New England BioLabs,
Missisauga, ON, Canada). Details of PCR conditions
have been described elsewhere [20]. The digested PCR
products were resolved on a 3% agarose gel and stained
with ethidium bromide for visualization under UVlight. For quality control, two independent observers,
read all genotypes without knowing about the case or
control status. Direct DNA sequencing was performed
to confirm the genotyping results.
Statistical analysis
All statistical tests were performed using the program
SPSS (SPSS Inc., Chicago, IL). Linkage disequilibrium
was calculated by EXCEL and the method of Chakravarti
et al. [21]. Hardy–Weinberg equilibrium was assessed by
the x2 goodness-of-fit test. Differences between continu-
ous variables were assessed by Student’s t test, while
those between categorical variables were evaluated using
Pearson x2 test. The existence of differences in genotypic
frequencies between groups was assessed by means of
Pearson x2 test and calculating the odds ratio (OR) with
the 95% confidence intervals (CI). OR adjusted for other
covariables (hypertension, diabetes, smoking, age and gen-
der) were determined using logistic regression models.
We also use the Bonferroni correction for total number of
independent comparisons. A P-value was considered sig-
nificant at a level of <0.05.
Results
Characteristics of participants
General characteristics of cases and controls were showed
in Table 1. No significant differences were found between
the CAD cases and controls in age, gender, family history,
hypertension, ApoA1 and ApoB (Table 1). Univariate study
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diabetes (P < 0.001), obesity (P < 0.001), hyperlipidemia
(P < 0.001), TG (P < 0.001), TC (P < 0.001), HDL-C (P =
0.002), LDL-C (P = 0.001) and VLDL-C (P < 0.001) were
risk factors of CAD (Table 1). Hardy–Weinberg propor-
tions were observed for all the SNPs. The 1100 C/T and
3238 C/G in the APOC3 gene are in complete linkage
disequilibrium in the Chinese population (Table 2).
APOC3 3238 C/G polymorphisms, lipids and CAD
Patients with CAD had a significantly higher frequency
of APOC3 3238 GG genotype (OR =1.64, 95% CI =1.10,
2.43; P = 0.01) and APOC3 3238 G allele (OR =1.27, 95%
CI =1.04, 1.55; P = 0.02) than controls (Table 2). The
findings are still emphatic by the Bonferroni correction.
When stratifying by hyperlipidemia, CAD patients with
hyperlipidemia had a significantly higher frequency of
APOC3 3238 GG genotype (OR =1.73, 95% CI =1.13,
2.64; P = 0.01) than without hyperlipidemia (Table 3). The
APOC3 3238 G allele was significantly associated with
increasing plasma TG levels and VLDL-C levels both in
cases and controls (P < 0.001) (Table 4).
APOC3 1100 C/T polymorphisms, lipids and CAD
No association was found between APOC3 1100 C/T
polymorphisms and CAD (Table 2). When stratifying by
smoking status, diabetes, obesity and hyperlipidemia, no
significant differences were found in any groups
(Table 3).
Discussion
A lot of studies have been conducted to examine the
association of genetic polymorphism and risk of CAD. A
meta-analysis of 9 studies that included 1,700 CAD
patients and 4,081 healthy controls suggested that ALDH2
Glu504Lys polymorphism may be associated with in-
creased risk of CAD and myocardial infarction in East
Asians, especially among Chinese and Korean populationsTable 2 Genotype and allele frequencies of APOC3 gene poly
healthy controls




1100 C allele frequency 650(54.2)




3238 C allele frequency 942(78.5)
3238 G allele frequency 258(21.5)[22]. A meta-analyses of 26 studies that included 12,776
cases and 6,371 controls found that -1562C>T polymorph-
ism in the promoter region of matrix metalloproteinase-9
may have association with CAD risk in Asian populations
[23]. A meta-analyses of 22 studies including 3,502 CAD
patients and 3,071 controls suggested that the angiotensin
II receptor, type 1 gene A1166C polymorphism might
be a genetic marker for the development of CAD in
Chinese populations, especially in the context of studies
with northern and older subjects [24,25]. A meta-
analyses of 11 studies involving 22,584 subjects showed
that PTGS2 -765G/C was associated with a decreased
risk of CAD [26]. A meta-analyses of ten studies with
4,413 patients found that apolipoprotein M T-778C
polymorphism was associated with serum lipid levels
and the risk of CAD in the Chinese population [27]. A
meta-analyses of 11 studies involving 5,535 CAD pa-
tients and 5,626 controls indicated that the Connexin37
C1019T polymorphism may be a moderate risk factor
for CAD [28]. A meta-analyses of 20 studies comprising
15,591 participants found that apolipoprotein C3 Sst I
and T-455C polymorphisms might be associated with
CAD risk [14]. A meta-analyses of 9 studies that in-
cluded 3,439 cases and 14,182 controls suggested that
Cyclooxygenase-2 (COX-2) rs20417 polymorphism may
contribute to CAD development, especially in Asians
[29]. A prospective case–control study found that the
rsl2221497 polymorphism in liver X receptor alpha gene
was associated with susceptibility of CAD in Han popu-
lation [30]. A meta-analyses of 40 studies including
4,564 CAD cases and 3,985 controls suggested an asso-
ciation between apolipoprotein E (ApoE) epsilon4 allele
and increased risk of CAD in Chinese population [31].
The APOC3 gene polymorphisms were also associated
with many other diseases. The polymorphisms −482 C/T
and −455 T/C in APOC3 were associated with nonalco-
holic fatty liver disease and insulin resistance [32]. A
case–control study suggested that APOC3 1100 C/T wasmorphisms among coronary artery disease cases and











Table 3 Stratification analysis of APOC3 3238 C/G polymorphisms in coronary artery disease cases
Cases CC CG GG
n (%) OR (95% CI) P n (%) OR (95% CI) P n (%) OR (95% CI) P
Smoking status 600 414(69.0) 1(Reference) 114(19.0) 1(Reference) 72(12.0) 1(Reference)
Ever 192 133(69.3) 1.00(0.78,1.29) 0.98 35(18.2) 0.96(0.64,1.45) 0.84 24(12.5) 1.04(0.64,1.70) 0.87
Never 408 281(68.9) 0.99(0.82,1.22) 0.99 79(19.4) 1.02(0.75,1.39) 0.91 48(11.7) 0.98(0.67,1.44) 0.92
Diabetes 600 414(69.0) 1(Reference) 114(19.0) 1(Reference) 72(12.0) 1(Reference)
Positive 156 107(68.6) 0.99(0.75,1.31) 0.97 30(19.2) 1.01(0.65,1.57) 0.96 19(12.2) 1.02(0.59,1.73) 0.96
Negative 444 307(69.1) 1.00(0.83,1.21) 0.98 84(18.9) 1.00(0.73,1.35) 0.98 53(11.9) 0.99(0.68,1.45) 0.98
Obesity 600 414(69.0) 1(Reference) 114(19.0) 1(Reference) 72(12.0) 1(Reference)
Positive 176 120(68.2) 0.99(0.76,1.29) 0.93 35(19.9) 1.05(0.69,1.58) 0.83 21(11.9) 0.99(0.60,1.66) 0.98
Negative 424 294(69.3) 1.01(0.83,1.22) 0.96 79(18.6) 0.98(0.72,1.34) 0.90 51(12.0) 1.00(0.69,1.47) 0.99
Hyperlipidemia 600 414(69.0) 1(Reference) 114(19.0) 1(Reference) 72(12.0) 1(Reference)
Positive 188 117(62.2) 0.90(0.69,1.17) 0.44 32(17.0) 0.90(0.59,1.37) 0.61 39(20.7) 1.73(1.13,2.64) 0.01
Negative 412 297(72.1) 1.05(0.86,1.27) 0.66 82(19.9) 1.05(0.77,1.43) 0.77 33(8.0) 0.67(0.43,1.03) 0.07
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through mechanisms other than direct effects on TG
[33]. A population-based prospective cohort (n =7,983)
APOC3 -482T allele had increased type 2 diabetes risk
[34]. APOC3 gene polymorphisms contributed to an un-
favorable lipid profile in patients with HIV [13]. A case–
control study suggested that the minor alleles of APOC3
-455 T/C polymorphisms were closely associated with
acute coronary syndrome [35]. A case–control study
suggested that APOC3 -482TT genotype was independ-
ently associated with elevated fasting triglyceride con-
centrations in obese men [36]. A case–control study
involving 374 Chinese type 2 diabetic patients with and
392 without diabetic nephropathy found that the hepatic
lipase -514C/T polymorphism interaction with polymor-
phisms in APOC3 -482C/>T increased the risk of dia-
betic nephropathy [37]. A case–control study suggested
that APOC3 SstI polymorphism was weakly associated
with sporadic Alzheimer's disease in a Chinese population
[38]. A case–control study suggested that APOC3 pro-
moter polymorphisms (−482 C/T and −455 T/C) were
associated with the metabolic syndrome [39,40].Table 4 Lipid profiles of coronary artery disease cases and co
CAD P
CC CG GG
TG (mg/dL) 162.3 ± 86.5 197.6 ± 90.4 253.9 ± 104.7 <
TC (mg/dL) 199.4 ± 58.5 215.4 ± 62.7 196.3 ± 58.4
HDL-C (mg/dL) 37.5 ± 11.1 40.8 ± 10.4 31.5 ± 9.8
LDL-C (mg/dL) 127.1 ± 49.8 128.8 ± 49.8 105.7 ± 42.3
VLDL-C (mg/dL) 34.8 ± 19.8 45.8 ± 24.1 59.1 ± 27.4 <
ApoA1 (mg/dL) 124.6 ± 22.9 138.4 ± 25.6 125.2 ± 23.4
ApoB (mg/dL) 88.3 ± 28.1 99.8 ± 30.1 89.1 ± 27.9Although the exact mechanism by which the APOC3
3238 G allele might contribute to an increased risk of
CAD is still unclear, it is widely suspected that as a
result of its effect on lipid metabolism. A meta-analyses
of 29 Western prospective studies involving 262,525
participants indicated moderate and highly significant
associations between triglyceride values and CAD risk
[41]. The Bogalusa Heart Study found that APOC3
3238 C/G polymorphisms were associated with higher
serum triglyceride levels [42]. Our study also found that
the APOC3 3238 G allele was significantly associated
with increasing plasma TG levels and VLDL-C levels.
Strength of this study was a relatively large sample size.
Several limitations of our study should be addressed. First
of all, potential selection bias might have been present,
because this is a hospital based case control study and the
subjects may not be representative of the general popula-
tion. Second, this study only considers a Chinese popula-
tion that may limit the application of these findings to
other ethnic populations. Third, CAD is induced by mul-
tiple genes and environmental factors, which were not
explored in the present study.ntrols according to APOC3 3238 C/G polymorphisms
value Controls P value
CC CG GG
0.001 138.7 ± 75.8 170.5 ± 80.6 224.6 ± 95.7 <0.001
0.65 182.3 ± 47.1 213.8 ± 49.8 194.4 ± 48.7 0.74
0.56 37.4 ± 11.7 46.2 ± 14.5 41.7 ± 12.4 0.52
0.09 115.3 ± 34.9 130.6 ± 37.4 104.5 ± 32.7 0.34
0.001 29.6 ± 18.7 37.0 ± 20.1 48.2 ± 21.3 <0.001
0.78 124.5 ± 22.1 135.6 ± 24.1 124.7 ± 21.8 0.68
0.73 87.3 ± 24.2 97.7 ± 28.7 91.4 ± 25.7 0.82
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In conclusion, our study suggested that the APOC3
3238 G allele might contribute to an increased risk of
CAD as a result of its effect on TG and VLDL-C metabol-
ism. Additional studies are needed to confirm this finding.
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